- Mutations in epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) fusion oncogene
|
-
Pulmonary lymphoepithelioma-like carcinoma subtype of NSCLC
|
-
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
|
-
Active or history of autoimmune disease or immune deficiency
|
-
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
|
-
History of malignancy other than NSCLC within 5 years prior to randomization, with the exception of malignancies with a negligible risk of metastasis or death
|
-
Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety
|
-
Treatment with investigational therapy within 28 days prior to initiation of study treatment
|
-
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
|
-
Please contact study team for additional exclusion criteria
|